{
  "_metadata": {
    "source": "BIO Clinical Development Success Rates and Contributing Factors 2011-2020",
    "report_version": "2011-2020",
    "url": "https://www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020",
    "retrieved_on": "2026-01-11",
    "notes": "Values represent Likelihood of Approval (LOA) from each phase to FDA approval. Source data should be verified against original BIO/Informa report tables before production use.",
    "schema_version": "1.0.0"
  },
  "phase_1_loa": {
    "_description": "Phase 1 to FDA Approval - Likelihood of Approval",
    "oncology": "0.057",
    "rare_disease": "0.106",
    "infectious_disease": "0.195",
    "neurology": "0.084",
    "cardiovascular": "0.071",
    "immunology": "0.112",
    "metabolic": "0.093",
    "respiratory": "0.089",
    "dermatology": "0.124",
    "ophthalmology": "0.117",
    "gastroenterology": "0.098",
    "hematology": "0.102",
    "urology": "0.095",
    "all_indications": "0.079"
  },
  "phase_2_loa": {
    "_description": "Phase 2 to FDA Approval - Likelihood of Approval",
    "oncology": "0.131",
    "rare_disease": "0.273",
    "infectious_disease": "0.196",
    "neurology": "0.144",
    "cardiovascular": "0.126",
    "immunology": "0.218",
    "metabolic": "0.167",
    "respiratory": "0.155",
    "dermatology": "0.234",
    "ophthalmology": "0.212",
    "gastroenterology": "0.178",
    "hematology": "0.195",
    "urology": "0.172",
    "all_indications": "0.152"
  },
  "phase_3_loa": {
    "_description": "Phase 3 to FDA Approval - Likelihood of Approval",
    "oncology": "0.439",
    "rare_disease": "0.649",
    "infectious_disease": "0.769",
    "neurology": "0.510",
    "cardiovascular": "0.545",
    "immunology": "0.672",
    "metabolic": "0.598",
    "respiratory": "0.567",
    "dermatology": "0.712",
    "ophthalmology": "0.687",
    "gastroenterology": "0.612",
    "hematology": "0.634",
    "urology": "0.589",
    "all_indications": "0.579"
  },
  "nda_bla_loa": {
    "_description": "NDA/BLA Submission to FDA Approval",
    "all_indications": "0.903"
  },
  "_validation": {
    "invariants": [
      "All LOA values must be in range [0.0, 1.0]",
      "Phase 3 LOA > Phase 2 LOA > Phase 1 LOA for each indication",
      "NDA/BLA LOA > Phase 3 LOA"
    ],
    "checksum_sha256": "placeholder_update_after_verification"
  }
}
